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Background: Bisphosphonates are the most commonly prescribed osteoporosis drugs but long-term effects are unclear, although
antitumour properties are known from preclinical studies.
Methods: Nested case–control studies were conducted to investigate bisphosphonate use and risks of common non-
gastrointestinal cancers (breast, prostate, lung, bladder, melanoma, ovarian, pancreas, uterus and cervical). Patients 50 years and
older, diagnosed with primary cancers between 1997 and 2011, were matched to five controls using the UK practice-based
QResearch and Clinical Practice Research Datalink (CPRD) databases. The databases were analysed separately and the results
combined.
Results: A total of 91 556 and 88 845 cases were identified from QResearch and CPRD, respectively. Bisphosphonate use was
associated with reduced risks of breast (odds ratio (OR): 0.92, 95% confidence interval (CI): 0.87–0.97), prostate (OR: 0.87, 95% CI:
0.79–0.96) and pancreatic (OR: 0.79, 95% CI: 0.68–0.93) cancers in the combined analyses, but no significant trends with duration.
For alendronate, reduced risk associations were found for prostate cancer in the QResearch (OR: 0.81, 95% CI: 0.70–0.93) and
combined (OR: 0.84, 95% CI: 0.75–0.93) analyses (trend with duration P-values 0.009 and 0.001). There were no significant
associations from any of the other analyses.
Conclusion: In this series of large population-based case–control studies, bisphosphonate use was not associated with increased
risks for any common non-gastrointestinal cancers.
Bisphosphonates were introduced as a treatment for postmeno-
pausal osteoporosis (National Institute for Health and Clinical
Excellence, 2008a, b) in the 1990s, and prescribing has substantially
increased (Kanis et al, 2008). The effects of bisphosphonates are
long term as the drugs accumulate in bones and are released for
several years after treatment ends (Watts and Diab, 2010). It is a
relatively new treatment and very few studies have looked at the
long-term effect of bisphosphonates on risks of different cancers in
the general population.
Although antitumour properties of bisphosphonates have been
discovered in preclinical studies (Croucher et al, 2003; Guise, 2008)
and reaffirmed in the treatment of bone metastases (Gnant, 2010),
no long-term randomised clinical trials have been run to determine
the effect of bisphosphonates on cancer incidence. Epidemiological
studies have consistently reported a reduced risk of breast cancer in
bisphosphonate users (Chlebowski et al, 2010; Newcomb et al,
2010; Rennert et al, 2010; Vestergaard et al, 2011; Cardwell et al,
2012), but the effects of bisphosphonates on other common non-
gastrointestinal cancers are still uncertain, having been investigated
in only one up-to-date observational study using the Clinical
Practice Research Datalink (CPRD) (Cardwell et al, 2012).
Previous studies have generally been insufficiently powered to
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detect associations for other types of cancer, and few have looked
at associations with individual types of bisphosphonate drugs, and
so there is little data to establish definitive conclusions. Our aim,
therefore, was to investigate the associations between bisphos-
phonates and risks of common cancers in the general population
using a nested case–control design and including all available data
from two large primary-care databases – both the QResearch and
the CPRD.
MATERIALS AND METHODS
Data source. The two largest primary-care databases in the UK,
QResearch and CPRD, were used. Each database covers around 6%
of the UK population from more than 600 general practices, and
contains electronic records including patient demographics,
referrals, tests and prescriptions. Both are representative of the
general population in the United Kingdom, have been rigorously
validated using other sources of information (Jick et al, 2003;
Hippisley-Cox et al, 2004) and have been used for a range of safety
studies involving commonly prescribed medications (Green et al,
2010; Hippisley-Cox and Coupland, 2010; Parker et al, 2010;
Walker et al, 2011). The protocol for this study was published in
Vinogradova et al (2012) and, although originally based on
QResearch, a replicate study has also been conducted using CPRD
to examine any possible differences between the two and further
increase in the statistical power by running analyses to derive
combined results from both data sources.
Study design. Open cohorts of patients were identified in each
database: patients were aged 50 years and older and registered with
the practice at some time during the study period between January
1997 and July 2011. For this paper, we selected the most common
solid, non-gastrointestinal cancers (breast, prostate, lung, bladder,
pancreatic, ovarian and melanoma) as the outcomes and identified
incident cases from the cohorts. Less common female cancers
(cervix and uterus) were also considered. Each case was matched to
up to five controls by age, sex, practice and calendar year. All
controls were alive and registered with the practice at the date of
the first recorded diagnosis of cancer in their matched case, which
we defined as the index date for each case and their matched
controls. For cases and controls, patients were included only if they
had at least 2 years of data before their index date. Cases and
controls with bisphosphonate prescriptions licensed for any
malignancies before the index date (date of diagnosis for cases or
equivalent date for controls) were excluded. For breast cancer, male
patients and patients with a record of mastectomy before their first
prescription of bisphosphonates were excluded. Patients with
Paget’s disease were also excluded.
Exposure to bisphosphonates. Exposure to bisphosphonates was
assessed, including prescriptions for alendronate, etidronate,
ibandronate and risedronate as the nationally licensed drugs for
the treatment of osteoporosis (BNF 6.6.2) (British Medical
Association and Royal Pharmaceutical Society of Great Britain,
2008). Information was extracted on all prescriptions for bisphos-
phonates during the observation period – defined as a period
between the date of patient registration with the general practice
and 6 months before the index date. Prescriptions in the past 6
months before the index date were not used to reduce protopathic
bias because early symptoms of cancer such as low weight or bone
ache could lead to bisphosphonate treatments. For the main
analyses, a patient was considered to be a bisphosphonate user if
they had at least one prescription during the observation period.
Cumulative exposure was estimated by summing the durations of
all bisphosphonate prescriptions for each patient, considering gaps
of fewer than 90 days between two prescriptions as continuous
therapy. Duration of exposure to bisphosphonates was analysed
using the following categorisations: no use; short-term use (used
foro1 year); long-term use (used for41 year). For analyses of the
most common cancers (breast, prostate, lung, bladder and
melanoma), finer categories for duration of use of bisphosphonates
were considered: no use,o6 months; 7–36 months; 37–72 months;
and 73 months or more. A test for trend was performed using the
actual number of months.
Confounding variables. All the analyses included potential
confounders established as risk factors for cancer. Body mass
index (BMI) (Henderson and Bernstein, 2008), a continuous
variable, was based on values recorded at the date closest to 1 year
before the index date. Using Read codes, smoking status (Hecht,
2008) (current smoker – light (1–9 cigarettes per day), medium
(10–19), heavy (20 or more), ex-smoker, non-smoker); alcohol
consumption (Schu¨tze et al, 2011); and ethnicity (Ferlay et al,
2010) (White or not recorded, Black, Asian, Other) used values
recorded at the closest date before the index date. The analysis also
adjusted for history of osteoporosis (McGlynn et al, 2008),
including diagnosis of osteoporosis or osteopenia or previous
fractures (recorded before the index date); use of drugs increasing
risks of fracture and cancer such as systemic corticosteroids
and acid-suppressive medications (including H2 antagonists
(BNF 1.3.1), proton pump inhibitors (BNF 1.3.5) and antacids
(BNF 1.1.1)); (Corley et al, 2010) use of anti-inflammatory drugs
(Coussens and Werb, 2002) (traditional non-steroidal anti-
inflammatory drugs, cyclo-oxygenase 2 inhibitors and aspirin);
(Gonzalez-Perez et al, 2003) and use of vitamin D (Mocellin, 2011)
if they were prescribed at least 1 year before the index date. For
female cancer patients, use of hormone replacement therapy and
oral contraceptive pills were also added to the analyses.
If they were diagnosed at least a year before the index date,
comorbidities, which affect risks of cancer, were also included:
rheumatoid arthritis (Thomas et al, 2000) for any cancer; benign
breast disease for breast cancer; diabetes for pancreatic (Vincent
et al, 2011) and uterine (Burbos et al, 2010) cancers; hypertension
for uterine cancer (Bangalore et al, 2011); and gastrointestinal
disorders for pancreatic cancer (Vinogradova et al, 2012).
The results were also adjusted for cancer-specific family histories
of cancer (Mai et al, 2011) (to reduce recall bias in cases only if
recorded at least 6 months before the index date; Chang et al,
2006).
Statistical analysis. This study used conditional logistic regression
to estimate odds ratios with 95% CIs for cancers at each selected
site. The Wald test was used for estimating the effects of duration
and testing for differences between bisphosphonate types. Missing
values for the confounding factors (BMI, smoking status and
alcohol intake) were imputed using ICE multiple imputation
program in Stata (StataCorp LP, College Station, TX, USA)
(Royston, 2005) where all the confounding variables and exposure
to bisphosphonates were included into the models. Ten imputed
data sets were created and the results were combined using Rubin’s
rules (Royston, 2004).
Each database was analysed separately and the results combined
using the method of Mantel and Haenszel for fixed-effect models.
The primary analyses were based on bisphosphonate exposure
excluding prescriptions in the 6 months before the index date. Five
sensitivity analyses were carried out for each data set. The first was
to eliminate possible bias by redefining bisphosphonate exposure
as at least two prescriptions and considering patients with one
prescription only as non-users. Such patients might never have
started treatment or have soon stopped it because of adverse
gastrointestinal effects. The second sensitivity analysis was based
on all prescriptions before the index date including the ones issued
in the past 6 months. This aimed to eliminate another form of bias
caused by a possible oversampling of unexposed cases and controls
in the main analyses. The third sensitivity analysis was run on
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patients with at least 6 years of medical records and redefined
exposure based on prescription information only between 72 and 6
months before the index date. This was to eliminate possible bias
arising from the different observation times for patients in the
main analyses.
Townsend scores, a measure of deprivation, were available for
only 49% of CPRD practices, and only 36% of CPRD patients had
it recorded. Deprivation, therefore, was not included as a
confounding variable in any of the main analyses. The fourth
sensitivity analysis included Townsend scores as a confounding
variable, but was run only on patients with a valid code. The fifth
and final sensitivity analysis was run on observations with recorded
values for BMI, smoking status and alcohol consumption. For the
fourth and fifth sensitivity analyses, the definitions for use of
bisphosphonates and years of medical records were identical to the
main analysis.
Although sample size calculations were carried out and
presented in the protocol (Vinogradova et al, 2012), all available
data were used in the analyses. We considered a 1% level as
statistically significant to allow for multiple comparisons, but
have presented 95% CIs in our results to create parity with other
studies. Stata Version 12 was used for all analyses.
RESULTS
Study population. Within the study period, we identified 91 556
and 88 845 cases of cancers of interest in people aged 50 years and
older from QResearch and CPRD, respectively. These were
matched to 427 674 and 415 583 controls, respectively, all with at
least 2 years of medical records (Figure 1). Median years of
available records was 17 (interquartile range 10–28 in QResearch
cases and controls, 10–29 in CPRD cases and 10–30 CPRD
controls), and it was consistent both for cancer sites and for cases
and controls. Table 1 shows the numbers of cases and controls for
each cancer site and also the characteristics of the study
population. QResearch and CPRD provided similar samples from
the general population. The QResearch cases and controls were
about the same age (mean 69.4 years, standard deviation 9.8 in
cases; 69.4 years, 9.7 in controls) as CPRD (69.9 years, 10.4
in cases; 69.7 years, 10.2 in controls) but included fewer women
(48% vs 51%), and so had slightly different incidences in cancers
of interest.
The proportion of bisphosphonate users (4.2%) was the same in
both databases and in cases and controls, with similar proportions
of patients prescribed different types of bisphosphonates. Figure 2
shows that in both databases the proportion of cases and controls
with at least one bisphosphonate prescription consistently grew
from 1% in 1997 to 7% in 2011. Use of etidronate decreased but
use of alendronate and risedronate increased, for alendronate
reaching over 80% for bisphosphonate users with at least one
prescription. Most bisphosphonate users were older than 60 years
(92% in both databases) and their median duration of use was 20
months (interquartile range 7–43) in cases and controls in
QResearch and 19 months (6–40 in cases and 6–41 in controls)
in CPRD. The median duration varied slightly between the cancer
sites, from 16.5 months for cervix cases and 27 for melanoma cases
in QResearch, and 17 for lung cancer cases to 22.5 for melanoma
cases in CPRD. A much higher proportion of women were users
than men (6.6% women vs 2.0% men in cases, 6.8% women vs 1.7%
men in controls for QResearch, 6.5% women vs 1.9% men in cases
and 6.6% women vs 1.7% men in controls for CPRD). Use of
bisphosphonates did not necessarily follow a recorded diagnosis
of osteoporosis/osteopenia or a history of fractures; over 30%
of bisphosphonate users did not have either factor recorded
(38% cases and 36% controls in QResearch and 36% cases and
34% controls for CPRD).
Table 2 shows the number and proportion of cases and controls
who were bisphosphonate users for each cancer site and overall use
of the drug by database. Figure 3 contains the results of combined
analyses for overall bisphosphonate use. Table 3 presents trend test
results along with odds ratios for short- and long-term use for the
seven most common cancers. Table 4 shows further analyses for
the associations of different types of bisphosphonate use with
breast, prostate and lung cancer risks.
Breast cancer. Overall use of bisphosphonates was associated with
a reduced risk of breast cancer but it was only significant in
QResearch analyses (adjusted odds ratio (AOR): 0.89, 95%
CI: 0.82–0.97) and the combined analyses (AOR: 0.92, 95% CI:
0.87–0.98). Clinical Practice Research Datalink analyses demon-
strated a similar direction of the association (AOR: 0.95, 95% CI:
0.88–1.03), but it was not statistically significant (P¼ 0.2). None of
the associations were duration-dependent, with the only statisti-
cally significantly decreased risk for QResearch (P¼ 0.008) in
the subcategory between 7 and 36 months (AOR: 0.87, 95% CI:
0.78–0.96 for QResearch; 0.95, 0.86–1.05 for CPRD; 0.91, 0.85–0.98
for combined). The risks did not vary between bisphosphonate
types and none of them had statistically significant associations
with breast cancer risk.
The sensitivity analysis, which defined bisphosphonate use as at
least two prescriptions, demonstrated an even stronger reduced
association with breast cancer risk (AOR: 0.87, 95% CI: 0.80–0.94,
Po0.001 for QResearch; 0.94, 0.87–1.01, P¼ 0.1 for CPRD; 0.90,
0.85–0.96, Po0.001 for combined), but it remained statistically
significant only for short-term use, and only for QResearch and
combined (AOR: 0.80, 95% CI: 0.71–0.91, Po0.001 for QResearch;
0.87, 0.80–0.94, Po0.001 for combined) but not for CPRD (AOR:
0.92, 95% CI: 0.82–.03). There was no significant association with
long-term use for any analyses.
Other female cancers. Although QResearch analyses for ovarian
cancer showed an almost 20% increased, but not statistically
significant, risk (AOR: 1.19, 95% CI: 0.96–1.47), CPRD analyses
had an opposite, and also not statistically significant, association
(AOR: 0.84, 95% CI: 0.67–1.04), with combined results showing no
association at all (AOR: 1.00, 95% CI: 0.86–1.16). None of the
results from the different databases were duration-dependent.
There was a significant association between risedronate use
and ovarian cancer risk for QResearch (24 exposed cases) and
the combined analyses (56 exposed cases) (AOR: 0.48, 95% CI:
0.31–0.75, P¼ 0.001 for QResearch; 0.62, 0.46–0.84, P¼ 0.002 for
combined). The CPRD analysis (32 exposed cases) showed a
reduced risk but not statistically significantly (AOR: 0.77, 95% CI:
0.52–1.16). The trend tests were not statistically significant
(P¼ 0.013 for QResearch; P¼ 0.6 for CPRD; P¼ 0.07 for
combined) and this was consistent across all sensitivity analyses.
Overall use of bisphosphonates was not associated with cervical
or uterine cancer risk for either database or for the combined
analyses. Further analyses demonstrated no associations with
duration of use.
Prostate cancer. Adjusted analyses in both databases demon-
strated a reduced risk associated with bisphosphonate use but not
significant (AOR: 0.90, 95% CI: 0.79–1.02 for QResearch; 0.84,
0.73–0.96 for CPRD), but contributing to a significant association
in the combined analysis (AOR: 0.87; 95% CI: 0.79–0.96).
Although neither of the databases showed a significant duration-
dependent association (QResearch Ptrend¼ 0.064; CPRD
Ptrend¼ 0.03), the combined analyses did (Ptrend¼ 0.005), with a
15% reduced risk associated with long-term use of bisphos-
phonates (AOR: 0.85,; 95% CI: 0.76–0.95).
Bisphosphonates and non-gastrointestinal cancers BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2013.383 797
Further analyses showed significantly reduced risks for
alendronate users in QResearch, with a greater reduced risk for
long-term users (AOR: 0.75; 95% CI: 0.62–0.92), which was
duration-dependent (Ptrend¼ 0.009). Clinical Practice Research
Datalink associations were directionally similar to QResearch but
not significant and also with lower risk for long-term users (AOR:
0.86; 95% CI: 0.70–1.05) and not duration-dependent
(Ptrend¼ 0.05), although contributing to a significant association
(AOR: 0.80; 95% CI: 0.70–0.92) and duration dependency
(Ptrend¼ 0.001) in the combined analysis.
All sensitivity analyses with other definitions of use were
consistent in showing a reduced risk in long-term alendronate
users apart from the one including prescriptions from the
past 6 months before the index date. This analysis also
QRESEARCH CPRD
Cancers of interest 1997–2011, cases and controls
with at least 2 years of data
Total: 92 159 and 431 730
Breast: 24 891 and 116 355
Prostate: 26 656 and 125 046
Lung: 18 019 and 84 428
Bladder: 7485 and 34 971
Melanoma: 5008 and 23 489
Ovary: 3431 and 16 127
Pancreas: 3597 and 16 870
Uterus: 2250 and 10 595
Cervix: 822 and 3849
Excluded from breast cancer sample
because of mastectomy:
392 controls (any time before index date)
337 cases (more than a year before the 
diagnosis)
3 cases with bisphosphonate use after the 
mastectomy in the last year
Excluded from all cancers because of
Paget’s disease:
224 cases, 817 controls
Excluded from all cancers because of
bisphosphonate prescription not for
osteoporosis:
39 cases, 50 controls
Excluded from all cancers because of 
absence of a case or control:
2 cases, 2795 controls
Remained cases and controls
Total: 91 556 and 427 674
Breast: 24 489 and 113 945
Prostate: 26 554 and 124 230 
Lung: 17 961 and 83 992
Bladder: 7464 and 34 786
Melanoma: 4998 and 23 399
Ovary: 3427 and 16 089
Pancreas: 3593 and 16 818
Uterus: 2248 and 10 570
Cervix: 822 and 3845
Cancers of interest 1997–2011, cases and controls
with at least 2 years of data
Total: 89 470 and 419 666
Breast: 25 860 and 121 331
Prostate: 23 268 and 108 865
Lung: 19 121 and 90 018
Bladder: 7106 and 33 179
Melanoma: 4631 and 21 734
Ovary: 3094 and 14 586
Pancreas: 3496 and 16 299
Uterus: 2153 and 10 159
Cervix: 741 and 3495
Excluded from breast cancer sample because
of mastectomy:
442 controls (any time before index date)
365 cases (more than a year before the 
diagnosis)
54 cases with bisphosphonate use after 
the mastectomy in the last year
Excluded from all cancers because of
Paget’s disease:
218 cases, 884 controls
Excluded from all cancers because of
bisphosphonate prescription not for 
osteoporosis:
27 cases, 37 controls
Excluded from all cancers because of 
absence of a case or control:
4 cases, 2877 controls
Remained cases and controls
Total: 88 845 and 415 383
Breast: 25 444 and 118 835
Prostate: 23 176 and 108 102
Lung: 19 059 and 89 471
Bladder: 7084 and 32 984
Melanoma: 4621 and 21 654
Ovary: 3088 and 14 532
Pancreas: 3485 and 16 200
Uterus: 2149 and 10 125
Cervix: 739 and 3480
Figure 1. Flow of the included patients for QResearch and CPRD analyses.
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Table 1. Baseline characteristics in cases and all matched controls by database (QResearch or CPRD)
QResearch CPRD
Cases Controls Cases Controls
Total 91 556 427674 88 845 415383
Breast 24 489 113945 25 444 118835
Prostate 26 554 124230 23 176 108102
Lung 17 961 83992 19 059 89471
Bladder 7464 34786 7084 32984
Skin 4998 23399 4621 21654
Ovary 3427 16089 3088 14532
Pancreas 3593 16818 3485 16200
Uterus 2248 10570 2149 10125
Cervix 822 3845 739 3480
Sex
Male 47 193 (51.5) 220 492 (51.6) 43 596 (49.1) 203 487 (49.0)
Female 44 363 (48.5) 207 182 (48.4) 45 249 (50.9) 211 896 (51.0)
Age band (years)
30–54 7345 (8.0) 34 000 (7.9) 6998 (7.9) 32 749 (7.9)
55–64 22 786 (24.9) 106 266 (24.8) 22 071 (24.8) 104 095 (25.1)
65–74 30 410 (33.2) 143 528 (33.6) 28 407 (32.0) 134 902 (32.5)
75–84 26 177 (28.6) 122 798 (28.7) 23 864 (26.9) 112 533 (27.1)
85þ 4838 (5.3) 21 082 (4.9) 7505 (8.4) 31 104 (7.5)
Ethnicity
White 21 477 (23.5) 90 874 (21.2) 7034 (7.9) 30 294 (7.3)
Not recordeda 69 131 (75.5) 331 241 (77.5) 78 841 (88.7) 371 491 (89.4)
Non-white 948 (1.0) 5559 (1.3) 2970 (3.3) 13 598 (3.3)
Asianb 364 (0.4) 2726 (0.6) 194 (0.2) 1516 (0.4)
Blackb 397 (0.4) 1834 (0.4) 166 (0.2) 649 (0.2)
Otherb 187 (0.2) 999 (0.2) 2610 (2.9) 11 433 (2.8)
Deprivation, Townsend quintile
1, most affluentc 23 442 (26.3) 110 919 (26.7) 9753 (30.5) 45 736 (30.6)
2c 19 959 (22.4) 94 167 (22.7) 7695 (24.0) 36 203 (24.2)
3c 18 032 (20.2) 84 427 (20.3) 6253 (19.5) 29 740 (19.9)
4c 15 768 (17.7) 72 202 (17.4) 5007 (15.6) 23 075 (15.4)
5, most deprivedc 12 075 (13.5) 53 799 (12.9) 3290 (10.3) 14 914 (10.0)
Not recorded 2280 (2.5) 12 160 (2.8) 56 847 (64.0) 265 715 (64.0)
BMI (kgm2)
15–24c 27 225 (38.0) 120 028 (37.3) 29 310 (39.1) 131 726 (38.3)
25–29c 28 956 (40.4) 130 874 (40.7) 29 808 (39.7) 138 713 (40.3)
30–49c 15 409 (21.5) 70 904 (22.0) 15 913 (21.2) 73 554 (21.4)
Not recorded 19 966 (21.8) 105 868 (24.8) 13 814 (15.5) 71 390 (17.2)
Smoking status
Non-smokerc 34 949 (41.4) 182 349 (48.0) 40 128 (47.6) 21 2180 (55.4)
Ex-smokerc 31 475 (37.3) 136 575 (36.0) 26 958 (32.0) 112 142 (29.3)
Current light smokerc 5633 (6.7) 20 787 (5.5) 3966 (4.7) 13 871 (3.6)
Current moderate smokerc 7825 (9.3) 26 747 (7.0) 8838 (10.5) 30 846 (8.1)
Current heavy smokerc 4467 (5.3) 13 187 (3.5) 4382 (5.2) 13 646 (3.6)
Not recorded 7207 (7.9) 48 029 (11.2) 4573 (5.1) 32 698 (7.9)
Use of alcohol
No usec 22 061 (29.9) 101 997 (30.5) 19 714 (25.8) 92 647 (26.6)
Ex usec 2030 (2.7) 7672 (2.2)
Lightc 44 809 (60.7) 203 342 (60.8) 44 448 (58.1) 204 556 (58.8)
Moderate and morec 7009 (9.5) 29 036 (8.7) 10 250 (13.4) 42 911 (12.3)
Not recorded 17 677 (19.3) 93 299 (21.8) 12 403 (14.0) 67 597 (16.3)
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demonstrated an increased risk for very short-term use (up to 6
months) but only in QResearch (AOR: 1.29; 95% CI: 1.08–1.53,
P¼ 0.004). As for overall bisphosphonate use, the sensitivity
analysis for at least two prescriptions reached a statistically
significant level in CPRD (AOR: 0.83, 95% CI: 0.72–0.95,
P¼ 0.008).
Lung cancer. After adjusting for confounders, there was no
significant association with bisphosphonate use (AOR: 0.97, 95%
CI: 0.88–1.08 in QResearch; 1.12, 1.01–1.23 in CPRD; 1.04, 0.97–
1.12 for combined). Further analyses demonstrated no associations
with duration or type of bisphosphonate.
Results were consistent in sensitivity analyses apart from
one – the sensitivity analysis, which included prescriptions from
the past 6 months before the index date showed increased risk
associated with short-term use in both databases (AOR: 1.34, 95%
CI: 1.18–1.52, Po0.001 for QResearch; 1.30, 1.15–1.47, Po0.001
for CPRD).
Bladder cancer. Adjusting for confounders showed no association
between bisphosphonate use and risk of bladder cancer (AOR:
0.96, 95% CI: 0.80–1.14 for QResearch; 0.94, 0.79–1.12 for CPRD;
0.95, 0.84–1.08 for combined). Sensitivity analyses also showed no
associations.
Melanoma. There was no association between overall bisphos-
phonate use and risk of melanoma in either database (AOR:
1.05, 95% CI: 0.87–1.28 for QResearch; 0.95, 0.77–1.19 for CPRD;
1.01, 0.87–1.17 for combined), and analyses did not show
statistically significantly increased risk with longer use in either
database or the combined (Ptrend¼ 0.013 for QResearch;
Ptrend¼ 0.5 for CPRD; Ptrend¼ 0.02 for combined). The results
were consistent across the sensitivity analyses, except for the one
defining use as at least one prescription between 6 and 72 months.
Table 1. ( Continued )
QResearch CPRD
Cases Controls Cases Controls
Comorbidities
Upper GI 19 250 (21.0) 83 377 (19.5) 24 302 (27.4) 107 660 (25.9)
Diabetes 8140 (8.9) 36 769 (8.6) 7990 (9.0) 37 011 (8.9)
Pancreatitis 492 (0.5) 1981 (0.5) 552 (0.6) 2102 (0.5)
Hypertension 31 466 (34.4) 142 577 (33.3) 31 169 (35.1) 142 474 (34.3)
Chronic kidney disease 3444 (3.8) 15 558 (3.6) 3710 (4.2) 16 425 (4.0)
Rheumatoid arthritis 1424 (1.6) 6591 (1.5) 1673 (1.9) 7310 (1.8)
Benign breast disease 2727 (3.0) 10 077 (2.4) 2761 (3.1) 9653 (2.3)
History of osteoporosis
Osteoporosis/osteopenia 3682 (4.0) 16 998 (4.0) 4023 (4.5) 18 474 (4.4)
Osteoporotic fractures 3322 (3.6) 16 013 (3.7) 2375 (2.7) 10 342 (2.5)
Family history of cancer 2841 (3.1) 11 756 (2.7) 2836 (3.2) 11 364 (2.7)
Medications (excluding past 6 months)
Acid-lowering drugs 32 523 (35.5) 14 0637 (32.9) 33 531 (37.7) 145 409 (35.0)
NSAIDs 52 422 (57.3) 233 143 (54.5) 55 106 (62.0) 248 518 (59.8)
Corticosteroids 14 156 (15.5) 57 106 (13.4) 13 908 (15.7) 54 233 (13.1)
Calcium 1023 (1.1) 4816 (1.1) 6286 (7.1) 28 984 (7.0)
Vitamin D 4891 (5.3) 22 582 (5.3) 4960 (5.6) 23 035 (5.5)
Hormone replacementd 12 071 (13.2) 51 861 (12.1) 12 633 (14.2) 55 666 (13.4)
Oral contraceptivesd 773 (0.8) 3551 (0.8) 1236 (1.4) 5490 (1.3)
Bisphosphonates
Any 3827 (4.2) 17 883 (4.2) 3769 (4.2) 17 490 (4.2)
Alendronate 2589 (2.8) 12 010 (2.8) 2538 (2.9) 11 969 (2.9)
Etidronate 1286 (1.4) 5949 (1.4) 1170 (1.3) 5471 (1.3)
Risedronate 851 (0.9) 3985 (0.9) 806 (0.9) 3715 (0.9)
Ibandronate 74 (0.1) 435 (0.1) 75 (0.1) 353 (0.1)
Other osteoporosis drugs
Any 319 (0.3) 1641 (0.4) 333 (0.4) 1685 (0.4)
Raloxifen 192 (0.2) 1032 (0.2) 217 (0.2) 1081 (0.3)
Strontium 95 (0.1) 456 (0.1) 97 (0.1) 509 (0.1)
Calcitonin 38 (0.0) 207 (0.0) 34 (0.0) 162 (0.0)
Abbreviations: CPRD¼Clinical Practice Research Datalink; GI¼gastrointestinal; NSAID¼ non-steroidal anti-inflammatory drugs. Values are numbers and %.
aAssumed White for the analyses.
bBroken down categories for non-White group.
cProportion only within recorded data.
dOnly for women cancers.
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Here use of etidronate in the QResearch analysis was associated
with increased risk of melanoma (AOR: 1.67, 95% CI: 1.23–2.26,
Po0.001); however, this association was not duration-dependent
(Ptrend¼ 0.02).
Pancreatic cancer. After adjusting for the confounders analyses in
both databases showed a reduced risk of pancreatic cancer in
bisphosphonate users, although it was not statistically signi-
ficant (AOR: 0.81, 95% CI: 0.64–1.01 for QResearch; 0.78,
0.63–0.97 for CPRD). The combined analysis, however, demon-
strated a statistically significant association (AOR: 0.79, 95% CI:
0.68–0.93). Short-term use was associated with an even lower
but not statistically significant risk in all analyses (AOR: 0.78,
95% CI: 0.57–1.06 for QResearch; 0.77, 0.57–1.02 for CPRD; 0.77,
1
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QResearch CPRD
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Figure 2. Proportion of cases and controls in QResearch and CPRD with at least one prescription of bisphosphonate by index year.
Table 2. Bisphosphonate use in cancer cases and controls, numbers and odds ratios (95% CIs) compared with non-use by database
QResearch CPRD Combined analysis
Cancer site
Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Pooled odds
ratio (95% CI)
P-value
Breasta 1304/6923 0.89 (0.82–0.97) 0.005 1324/6847 0.95 (0.88–1.03) 0.2 0.92 (0.87–0.97) 0.004
Prostateb 460/2150 0.90 (0.79–1.02) 0.1 376/1901 0.84 (0.73–0.96) 0.012 0.87 (0.79–0.96) 0.003
Lungc 1035/3809 0.97 (0.88–1.08) 0.6 1114/3911 1.12 (1.01–1.23) 0.03 1.04 (0.97–1.12) 0.2
Bladderd 274/1219 0.96 (0.80–1.14) 0.6 280/1263 0.94 (0.79–1.12) 0.5 0.95 (0.84–1.08) 0.4
Melanomae 241/1067 1.05 (0.87–1.28) 0.6 178/881 0.95 (0.77–1.19) 0.7 1.01 (0.87–1.17) 0.9
Ovaryf 204/939 1.19 (0.96–1.47) 0.1 170/937 0.84 (0.67–1.04) 0.1 1.00 (0.86–1.16) 1.0
Pancreasg 178/886 0.81 (0.64–1.01) 0.06 196/918 0.78 (0.63–0.97) 0.03 0.79 (0.68–0.93) 0.003
Uterush 99/671 1.07 (0.79–1.44) 0.7 96/636 0.95 (0.71–1.27) 0.7 1.00 (0.81–1.24) 1.0
Cervixi 32/219 0.78 (0.48–1.27) 0.3 35/196 1.21 (0.76–1.93) 0.4 0.98 (0.70–1.37) 0.9
Abbreviations: BMI¼body mass index; CI¼ confidence interval; CPRD¼Clinical Practice Research Datalink; GI¼gastrointestinal; NSAID¼nonsteroidal anti-inflammatory drugs. *Adjusted for
BMI, smoking status, alcohol consumption, ethnicity, rheumatoid arthritis, osteoporosis and fractures, use of other osteoporosis drugs, vitamin D, NSAIDs, corticosteroids, acid-lowering drugs
and years of data.
aAlso adjusted for family history of breast cancer, benign breast disease, use of oral contraceptives and hormone replacement therapy.
bAlso adjusted for family history of prostate cancer.
cAlso adjusted for family history of lung cancer.
dAlso adjusted for family history of cancer and chronic kidney disease.
eAlso adjusted for family history of cancer.
fAlso adjusted for family history of ovarian cancer, use of oral contraceptives and hormone replacement therapy.
gAlso adjusted for family history of GI cancer, GI disease, diabetes and history of pancreatitis.
hAlso adjusted for family history of cancer, hypertension, diabetes, use of oral contraceptives and hormone replacement therapy.
iAlso adjusted for family history of cancer, use of oral contraceptives and hormone replacement therapy.
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0.63–0.96 for combined) and there was also no trend for duration
of use.
A sensitivity analysis defining use as at least two prescriptions
reached statistically significant level for the CPRD analysis in
overall use (0.73, 0.59–0.91, P¼ 0.005) and for short-term use
(AOR: 0.65, 95% CI: 0.47–0.89, P¼ 0.008). The other sensitivity
analyses did not demonstrate any significant associations.
Additional information. Sensitivity analyses on patients with
valid BMI, smoking status and alcohol consumption data and on
patients with valid Townsend codes showed similar results, which
are available from the authors.
DISCUSSION
Summary. This study, based on medical records from the two
largest UK primary-care databases, showed that the use of
bisphosphonates was not associated with increased risks for any
of the most common solid non-gastrointestinal cancers. Decreased
risks of breast, prostate and pancreatic cancers had no duration
relationship with bisphosphonate use and were found only in
short-term users. Alendronate use, however, was associated with a
decreased risk of prostate cancer and this association was duration-
dependent.
Strengths and limitations. Based on the two largest primary-care
databases, including more recent data than previous studies and
covering the period when bisphosphonates have become much
more widely prescribed in the general population, our study
provides more data for investigating the duration effects of
bisphosphonate use and over longer periods than previous studies.
All eligible cancer cases and controls, alive or dead, were included
into the study. This representativeness of the databases, and the
lack of recall, selection and respondent biases, also makes the
results more generalisable.
The limitations include possible uncertainties in cancer
diagnosis. The selection of cases was based on the first record of
a cancer and the exact origin site may have been determined only
later, but this level of detail was not available across all records. A
systematic review based on GPRD validation studies reported that,
on average, 95% of diagnoses of cancer recorded on the GP
electronic record were confirmed by other data sources (Herrett
et al, 2010). Information about cancer stage and the results of
histological investigations were also not consistently recorded
across general practices and so were not used. Another limitation is
the potential misclassification of bisphosphonate use. The analyses
were based on prescriptions not on actual use and no data were
available on adherence to medications. There is no reason,
however, to suppose that non-adherence differs systematically
between cases and controls.
Other limitations include information bias and missing data.
Lack of symptom or family history records might arise simply
because the patients have not reported them. Information on
certain risk factors such as the level of physical activity, diet and
cancer screening tests (mammography, prostate-specific antigen
test) was also not reliably recorded, so these factors were not
included in the analyses. Further, results of any bone mineral
density tests were not consistently recorded and were not used in
the analysis, and so there might be some residual confounding.
Important confounders such as smoking or BMI had some missing
data, so these had to be imputed.
Bisphosphonate users. Comparisons between bisphosphonate
users and non-users reflect the recommendations for targeting
the group with osteoporosis, and so some characteristics and
comorbidities such as low BMI and rheumatoid arthritis in users
were expected as these are risk factors for primary osteo-
porosis. As secondary osteoporosis is more likely to develop
in patients with impaired digestion, use of acid-lowering drugs
and also use of corticosteroids (Mauck and Clarke, 2006;
Hippisley-Cox and Coupland, 2009) were much higher for
bisphosphonate users.
Breast cancer. Reduced breast cancer risk associated with bispho-
sphonates use has been shown in five studies to date, all smaller
than the current one (Chlebowski et al, 2010; Newcomb et al, 2010;
Rennert et al, 2010; Vestergaard et al, 2011; Cardwell et al, 2012).
No relation between risk and duration of use could suggest that
osteoporosis is responsible for such reductions (Chen et al, 2008).
Adjustments for osteoporosis, however, have demonstrated the
independent effect of bisphosphonates. Reduced risk associated
with recent, but not remote, use of bisphosphonates might also be
explained by a possible bisphosphonate-related prevention of
progress for undiagnosed cancers up to an invasive stage. This has
already been shown by Chlebowski’s study (Chlebowski et al, 2010)
and supported by studies in menopausal women with early-stage
breast cancer treated with bisphosphonates (Gnant, 2010).
Although an Israeli (Rennert et al, 2010) case–control study
showed a statistically significantly decreased risk associated with
more than a year of bisphosphonate use (AOR: 0.61, 95% CI: 0.50–
0.76), the study was subject to recall bias (participants reported
their past use of bisphosphonates) and selection bias (all
participants were alive at the moment of the interview). Another
case–control study (Newcomb et al, 2010) with similar limitations
in the design also reported a statistically significant trend
(Ptrend¼ 0.01) for duration of bisphosphonate use. A cohort study
of Cardwell et al (2012) showed risk reduction associated with
overall bisphosphonate use similar to ours (adjusted hazard ratio
(AHR): 0.79, 95% CI: 0.62–1.01), and also becoming not
statistically significant for patients with use of more than a year.
Although our results for different types of bisphosphonate were in
line with Vestergaard et al’s study (2011) for alendronate (AHR:
0.91, 95% CI: 0.81–1.03), the risk reduction for etidronate in our
study did not reach a statistically significant level.
Prostate cancer. The association between overall use of bispho-
sphonates and prostate cancer risk was similar to that for breast
cancer, also without statistically significant effects for therapy
duration. Although the association between alendronate use and
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Figure 3. Risk of cancer in patients prescribed bisphosphonates,
combined results for QResearch and CPRD analyses.
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decreased risk appeared to be significant even with a duration
relationship, it was found only in the QResearch database and
might again suggest a possible suppressing effect of alendronate
on an already existing in situ cancer (Tuomela et al, 2008).
In particular in the prostate, in vitro studies have observed sub-
stantial concentrations of nitrogen-containing bisphosphonates
(zolendronic acid and ibandronate) after administration of the
drug (Fournier et al, 2002), which could result in suppressed
angiogenesis in prostate tumours. The only epidemiological study
looking at prostate cancer with respect to bisphosphonate use has
also demonstrated lower risk for bisphosphonate users, although
not statistically significant (AHR: 0.71, 95% CI: 0.50–1.01)
(Cardwell et al, 2012).
Lung cancer. Our study showed no association between lung
cancer risk and bisphosphonate use. This is consistent with the
only other epidemiological study (Cardwell et al, 2012), which also
found a reduced risk for long-term users (AHR: 0.86, 95% CI:
0.63–1.17) but it was not statistically significant. The antitumour
properties of bisphosphonates might not be applicable in the lung
because it is not a site where bisphosphonates accumulate
(Fournier et al, 2002). The sensitivity analysis for all prescriptions
including the past 6 months showed a significantly increased risk
but without any duration relationship and in particular for short-
term users. This may simply suggest that a common symptom of
lung cancer, bone pain, is sometimes initially mistaken as
osteoporosis.
Pancreas. Although none of the database analyses showed
statistically significantly decreased risks associated with bisphos-
phonate use, the combined analysis did. The findings were
consistent with the only other epidemiological study (Cardwell
et al, 2012) for this cancer site (AHR: 0.84, 95% CI: 0.53–1.35).
The effects of bisphosphonates on growth and apoptosis in
Table 3. Bisphosphonate short- and long-term use in cancer cases and controls, numbers and odds ratios (95% CIs) compared with non-use by database
Cancer site QResearch CPRD Combined analysis
Terms of use
Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Pooled odds
ratio (95% CI)
P-value
Breast Trend 0.5 Trend 0.3 Trend 0.2
Short term
(less than a year)
462/2523 0.86 (0.77–0.97) 0.01 508/2620 0.95 (0.86–1.06) 0.4 0.91 (0.84–0.98) 0.02
Long term
(at least a year)
842/4400 0.91 (0.83–1.00) 0.05 816/4227 0.95 (0.86–1.04) 0.3 0.93 (0.87–0.99) 0.03
Prostate Trend 0.06 Trend 0.03 Trend 0.005
Short term
(less than a year)
186/838 0.95 (0.80–1.13) 0.6 149/764 0.84 (0.70–1.02) 0.07 0.90 (0.79–1.02) 0.1
Long term
(at least a year)
274/1312 0.86 (0.74–1.00) 0.06 227/1137 0.84 (0.71–0.99) 0.04 0.85 (0.76–0.95) 0.005
Lung Trend 0.7 Trend 1.0 Trend 0.8
Short term
(less than a year)
415/1351 1.04 (0.90–1.19) 0.6 467/1507 1.15 (1.01–1.32) 0.03 1.10 (1.00–1.21) 0.06
Long term
(at least a year)
620/2458 0.93 (0.82–1.05) 0.2 647/2404 1.09 (0.96–1.23) 0.2 1.01 (0.92–1.10) 0.9
Bladder Trend 0.3 Trend 0.6 Trend 0.3
Short term
(less than a year)
109/455 0.99 (0.79–1.26) 1.0 117/464 1.06 (0.84–1.33) 0.6 1.03 (0.87–1.21) 0.8
Long term
(at least a year)
165/764 0.93 (0.76–1.15) 0.5 163/799 0.86 (0.69–1.06) 0.2 0.90 (0.77–1.04) 0.2
Melanoma Trend 0.01 Trend 0.5 Trend 0.02
Short term
(less than a year)
77/400 0.91 (0.70–1.20) 0.5 64/354 0.88 (0.65–1.18) 0.4 0.90 (0.73–1.10) 0.3
Long term
(at least a year)
164/667 1.16 (0.92–1.45) 0.2 114/527 1.01 (0.78–1.31) 0.9 1.09 (0.92–1.29) 0.3
Ovaries Trend 0.4 Trend 0.1 Trend 0.7
Short term
(less than a year)
83/322 1.37 (1.04–1.81) 0.02 62/355 0.80 (0.59–1.08) 0.1 1.07 (0.87–1.31) 0.5
Long term
(at least a year)
121/617 1.08 (0.84–1.38) 0.6 108/582 0.86 (0.66–1.11) 0.2 0.96 (0.81–1.15) 0.7
Pancreas Trend 0.2 Trend 0.05 Trend 0.02
Short term
(less than a year)
63/316 0.78 (0.57–1.06) 0.1 71/336 0.77 (0.57–1.02) 0.07 0.77 (0.63–0.96) 0.02
Long term
(at least a year)
115/570 0.82 (0.63–1.06) 0.1 125/582 0.80 (0.62–1.02) 0.08 0.81 (0.67–0.97) 0.02
Abbreviations: CI¼ confidence interval; CPRD¼Clinical Practice Research Datalink. *Adjusted for the confounders listed in the footnote for Table 2. Bold values indicate statistical significance.
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Table 4. Bisphosphonate use for individual drugs in cancer cases and controls, numbers and odds ratios (95% CIs) compared with non-use by database
QResearch CPRD Combined analysis
Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Cases/
controls
Adjusted*odds
ratio (95% CI)
P-value Pooled odds
ratio (95% CI)
P-value
Breast, alendronate Trend 0.7 Trend 0.04 Trend 0.3
Any use 901/4627 0.98 (0.89–1.07) 0.6 892/4648 0.96 (0.88–1.05) 0.3 0.97 (0.91–1.03) 0.3
Short term
(less than a year)
409/2148 0.95 (0.85–1.08) 0.4 414/2085 1.00 (0.89–1.13) 0.9 0.98 (0.90–1.06) 0.6
Long term (at least a year) 492/2479 1.00 (0.89–1.12) 1.0 478/2563 0.92 (0.83–1.03) 0.2 0.96 (0.89–1.04) 0.3
Breast, etidronate Trend 0.1 Trend 0.8 Trend 0.2
Any use 453/2437 0.90 (0.81–1.01) 0.07 412/2246 0.91 (0.81–1.02) 0.1 0.91 (0.84–0.98) 0.02
Short term
(less than a year)
176/893 0.95 (0.80–1.13) 0.6 179/1018 0.88 (0.74–1.03) 0.1 0.91 (0.81–1.03) 0.1
Long term (at least a year) 277/1544 0.87 (0.76–1.00) 0.05 233/1228 0.94 (0.81–1.09) 0.4 0.90 (0.82–1.00) 0.04
Breast, risedronate Trend 0.9 Trend 0.3 Trend 0.5
Any use 281/1537 0.92 (0.80–1.06) 0.2 279/1492 0.96 (0.84–1.11) 0.6 0.94 (0.85–1.04) 0.2
Short term
(less than a year)
139/803 0.89 (0.73–1.07) 0.2 118/733 0.83 (0.68–1.02) 0.07 0.86 (0.75–0.99) 0.03
Long term (at least a year) 142/734 0.96 (0.80–1.16) 0.7 161/759 1.08 (0.90–1.29) 0.4 1.02 (0.90–1.17) 0.7
Prostate, alendronate Trend 0.009 Trend 0.05 Trend 0.001
Any use 292/1506 0.81 (0.70–0.93) 0.004 257/1299 0.88 (0.75–1.03) 0.1 0.84 (0.75–0.93) 0.001
Short term
(less than a year)
142/692 0.86 (0.71–1.05) 0.1 120/591 0.91 (0.74–1.13) 0.4 0.89 (0.77–1.02) 0.1
Long term (at least a year) 150/814 0.75 (0.62–0.92) 0.004 137/708 0.86 (0.70–1.05) 0.1 0.80 (0.70–0.92) 0.002
Prostate, etidronate Trend 0.9 Trend 0.6 Trend 0.8
any use 141/567 1.06 (0.87–1.30) 0.5 104/496 0.88 (0.70–1.10) 0.3 0.98 (0.84–1.14) 0.8
Short term
(less than a year)
55/223 1.10 (0.81–1.48) 0.6 34/209 0.69 (0.47–1.00) 0.05 0.91 (0.72–1.15) 0.4
Long term (at least a year) 86/344 1.04 (0.81–1.33) 0.8 70/287 1.02 (0.77–1.34) 0.9 1.03 (0.86–1.24) 0.8
Prostate, risedronate Trend 0.9 Trend 0.3 Trend 0.4
Any use 99/455 0.98 (0.77–1.23) 0.8 70/374 0.87 (0.66–1.13) 0.3 0.93 (0.78–1.10) 0.4
Short term
(less than a year)
38/208 0.83 (0.58–1.18) 0.3 32/165 0.90 (0.61–1.33) 0.6 0.86 (0.66–1.12) 0.3
Long term (at least a year) 61/247 1.09 (0.81–1.46) 0.6 38/209 0.83 (0.58–1.19) 0.3 0.98 (0.78–1.23) 0.8
Lung, alendronate Trend 0.5 Trend 0.4 Trend 0.3
Any use 696/2542 1.00 (0.89–1.12) 0.9 756/2701 1.05 (0.94–1.18) 0.4 1.03 (0.95–1.11) 0.5
Short term
(less than a year)
339/1114 1.07 (0.92–1.24) 0.4 386/1220 1.16 (1.01–1.34) 0.04 1.12 (1.01–1.24) 0.04
Long term (at least a year) 357/1428 0.93 (0.80–1.08) 0.3 370/1481 0.96 (0.83–1.11) 0.6 0.95 (0.85–1.05) 0.3
Lung, etidronate Trend 0.8 Trend 0.1 Trend 0.2
Any use 338/1262 1.04 (0.90–1.20) 0.6 356/1200 1.13 (0.98–1.31) 0.09 1.09 (0.98–1.20) 0.2
Short term
(less than a year)
139/500 1.02 (0.82–1.27) 0.9 161/502 1.15 (0.94–1.42) 0.2 1.09 (0.94–1.27) 0.3
Long term (at least a year) 199/762 1.05 (0.87–1.26) 0.6 195/698 1.12 (0.93–1.35) 0.2 1.08 (0.95–1.24) 0.2
Lung, risedronate 0.9 Trend 0.7 Trend 0.7
Any use 261/848 1.02 (0.86–1.21) 0.8 252/829 1.11 (0.94–1.31) 0.2 1.06 (0.94–1.20) 0.3
Short term
(less than a year)
125/380 1.05 (0.83–1.33) 0.7 126/412 1.06 (0.85–1.34) 0.6 1.06 (0.90–1.25) 0.5
Long term (at least a year) 136/468 0.98 (0.78–1.22) 0.8 126/417 1.13 (0.90–1.42) 0.3 1.05 (0.89–1.23) 0.6
Abbreviations: CI¼ confidence interval; CPRD¼Clinical Practice Research Datalink. *Adjusted for the confounders listed in the footnote for Table 2. Bold values indicate statistical significance.
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pancreatic cancer cells have been shown in vitro (Tassone et al,
2003) and in vivo (Takiguchi et al, 2012). No duration relationship
suggests, however, that as with breast and prostate cancers
bisphosphonates might inhibit growth only of already existing
tumours.
Other cancers. Our study has not shown any significant
associations between overall use of bisphosphonates and risk of
endometrial, ovarian or cervical cancers, but the numbers for
endometrial and cervical cancers were very low and the findings
were not consistent across the databases. An association found
between ovarian cancer and risedronate use was found only in
QResearch data and without a duration relationship. Previous
much smaller studies have suggested a possible decreased risk for
bisphosphonate users for ovarian (AHR: 0.64, 95% CI: 0.40–1.03)
and endometrial cancers (AHR: 0.64, 95% CI: 0.38–1.08 (Cardwell
et al, 2012) and AOR: 0.7, 95% CI: 0.4–1.2 (Fortuny et al, 2009)),
but the results also did not reach a statistically significant level. Our
finding of a decreased risk for bladder cancer, which was not
however statistically significant, was consistent with a previous
study (AHR: 0.67, 95% CI: 0.41–1.10, P¼ 0.11) (Cardwell et al,
2012). No statistically significant associations between bispho-
sphonate use and melanoma risk were found, similar to the earlier
study (AHR: 0.80, 95% CI: 0.53–1.20) (Cardwell et al, 2012).
CONCLUSION
We have conducted a series of large population-based case–control
studies in two primary-care databases examining the association of
bisphosphonates with risks of common cancers in the general
population and found associations with reduced risks for breast,
prostate and pancreatic cancers, but with no duration relationship
and only in short-term users. A duration-dependent reduced risk
associated with alendronate use was found for prostate cancer, but
only in the QResearch data. This study does not provide enough
evidence to conclude that bisphosphonates have protective effects
on cancer, but the results are reassuring regarding the safety of
bisphosphonates.
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